PhD, University of Illinois, 2003
MS, University of Illinois, 2001
BS, Iowa State University, 1998


Developing new therapeutics and biomaterials for improving human health


Cory Berkland’s lab studies pharmaceuticals and biomaterials with a particular emphasis on molecular design, drug formulation, and transport in the human body. Professor Berkland is a co-founder of Orbis Biosciences (acquired by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ:SVRA), Bond Biosciences, and several other start-ups. Professor Berkland is currently CEO of Bond Biosciences and is an executive and chairman of the board for Kinimmune and Axioforce.


Cory Berkland will join Washington University in St. Louis as a Professor in the Department of Biomedical Engineering and the Department of Chemistry in Fall 2023. He earned MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in chemical engineering from Iowa State University in Ames.